Clinical trials: Atezolizumab
Advanced Biliary Tract Cancer
GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）
To evaluate the efficacy and immune microenvironment changes in treatment-naïve advanced biliary tract cancer (BTC) patients receiving first-line standard therapy with gemcitabine/cisplatin (GemCis) combined with PD-1/PD-L1…
- Trial name
- BTC-IM-1 (NCT06988592)
- Testing
- GemCis plus PD-1/PD-L1 inhibitor
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)
This is a multi-center observational study of atezolizumab combination therapy in patients with unresectable, advanced and recurrent non-small cell lung cancer(NSCLC) or extensive disease small cell lung cancer(ED-SCLC).
- Trial name
- NCT04501497
- Where
- 148 sites in Japan
- Volunteers
- 1,221 people
- Sponsor
- Chugai Pharmaceutical
Advanced Gynecological Cancers, Ovarian Cancer
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
The clinical trial was a companion study to protocol CL-PTL-119 (A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects with Stage IIIb-IV Ovarian Cancer…
- Conditions
- Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
- Trial name
- NCT03073525
- Testing
- Vigil, Atezolizumab
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gradalis, Inc.
Cancer
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or…
- Trial name
- NCT03148418
- Testing
- Atezolizumab, Bevacizumab
- Where
- 170 sites in United States, Argentina and 30 more
- Volunteers
- 382 people
- Sponsor
- Hoffmann-La Roche
Cholangiocarcinoma
Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)
This pilot trial will be used to assess the activity, safety and feasibility of doublet immunotherapy and platinum-based chemotherapy in resectable intrahepatic cholangiocarcinoma with high risk features.
- Trial name
- ICC (NCT04989218)
- Testing
- Novel combination of chemotherapy and immunotherapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Endometrial Cancer
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent…
- Trial name
- EndoMAP (NCT04486352)
- Testing
- Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib
- Where
- 21 sites in United States
- Volunteers
- 148 people
- Sponsor
- Alliance Foundation Trials, LLC.
Hepatocellular Carcinoma
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
This is a phase Ib/II, dose escalation and dose expansion study of valemetostat (DS-3201) with atezolizumab and bevacizumab in patients advanced Hepatocellular carcinoma (HCC) who did not receive prior systemic therapy for…
- Trial name
- NCT06294548
- Testing
- Valemetostat, Atezolizumab, Bevacizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Alabama at Birmingham
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
This phase I/II trial studies the best dose and effect of pimasertib in combination with bintrafusp alfa in treating patients with cancer that has spread to the brain (brain metastases).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma
- Trial name
- NCT04789668
- Testing
- Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Small Cell Lung Carcinoma
A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
This is a phase IIIB, single-arm, single-country, multicenter study of the safety and efficacy of atezolizumab in combination with carboplatin plus etoposide in patients who have ES-SCLC and are chemotherapy-naive for their…
- Trial name
- MAURIS (NCT04028050)
- Testing
- Atezolizumab, Carboplatin, Etoposide
- Where
- 25 sites in Italy
- Volunteers
- 155 people
- Sponsor
- Hoffmann-La Roche
Cancer, Solid Tumor
ACTolog in Patients With Solid Cancers
The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.
- Trial name
- ACTolog (NCT02876510)
- Testing
- Fludarabine, Cyclophosphamide, IMA101 product
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Immatics US, Inc.
HCC - Hepatocellular Carcinoma, Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
This study is a multicenter retrospective clinical research, led by the First Affiliated Hospital of Wenzhou Medical University, and jointly conducted by other sub-centers.
- Trial name
- NCT07495735
- Testing
- No intervention (observational study)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Hepatocellular Carcinoma
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
To explore the efficacy and safety of candonilimab plus bevacizumab for patients with advanced hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab.
- Trial name
- NCT05760599
- Testing
- Candonilimab, Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shi Ming
Solid Tumors
A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors
A study to evaluate the safety, pharmacokinetics and anti-tumor activity of RO7300490 as a single agent or in combination with atezolizumab.
- Trial name
- NCT04857138
- Testing
- RO7300490, Atezolizumab
- Where
- 11 sites in Denmark, France and 3 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Metastatic or Locally Advanced Malignancies
CRAFT: The NCT-PMO-1602 Phase II Trial
Whole-genome and transcriptome sequencing of patients with advanced solid tumors enrolled in the NCT/DKTK MASTER (Molecularly Aided Stratification for Tumor Eradication Research) program revealed genetic alterations in a…
- Trial name
- NCT04551521
- Testing
- Vemurafenib, Cobimetinib, Atezolizumab
- Where
- 9 sites in Germany
- Volunteers
- 72 people
- Sponsor
- German Cancer Research Center
Cancer, Immunotherapy
Retrospective Study of COVID-19 Vaccines in Patients Undergoing Immunotherapy for Cancer.
The investigators wish to set up a pharmaco-epidemiological cohort within the Hospital Territorial Groups of the Cévennes-Gard Camargue, East-Hérault and Haute-Garonne and West Tarn on a specific population, patients undergoing…
- Trial name
- IVACOV (NCT05025514)
- Where
- 5 sites in France
- Volunteers
- 125 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Cutaneous Toxicity From ICI Therapy
Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) are associated with a wide variety of cutaneous immune-related adverse events (cirAEs). These cirAEs are reported to be the most common immune-related adverse events (irAEs) and the first to…
- Trial name
- NCT04898751
- Testing
- Immune checkpoint inhibitor (ICI)
- Where
- United States
- Volunteers
- 2,214 people
- Sponsor
- Johns Hopkins University
Liver Cancer
A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions
Hepatocellular carcinoma (HCC) is a common global malignancy. In China, the disease burden is substantial: HCC ranks fifth in cancer incidence and third in mortality, with a 5-year relative survival of only 14.4%.
- Trial name
- NCT07645209
- Testing
- Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Harbin Medical University
Breast Cancer, Estrogen Receptor-positive Breast Cancer
Pre-operative Immunotherapy Combination Strategies in Breast Cancer
International, open label, window of opportunity phase II trial that aims to evaluate the effects of immunotherapy based treatment combinations in women with untreated, histologically confirmed, operable, ER+, HER2-negative…
- Trial name
- ECLIPSE (NCT03395899)
- Testing
- Atezolizumab, Cobimetinib, Ipatasertib
- Where
- United Kingdom
- Volunteers
- 71 people
- Sponsor
- Queen Mary University of London
Solid Tumors
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in…
- Trial name
- NCT04589845
- Testing
- Entrectinib, Alectinib, Atezolizumab
- Where
- 112 sites in United States, Australia and 21 more
- Volunteers
- 920 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
A Prospective, Multicenter, Non-Interventional Study of Primary Data Collection, Designed to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcomes in Patients with Breast Cancer in Latin America.
- Trial name
- NCT04158258
- Testing
- Bevacizumab, Trastuzumab, Ado-trastuzumab emtamsine
- Where
- 30 sites in Argentina, Brazil and 8 more
- Volunteers
- 2,907 people
- Sponsor
- Hoffmann-La Roche